Literature DB >> 27030054

Acute effect of rosiglitazone on relaxation responses in hypercholesterolemic corpus cavernosum.

H Akdag1, N Murat1, S Evcim1, A Esen2, S Gidener1.   

Abstract

Thiazolidinediones (TZDs) improve vascular endothelial dysfunction through non-genomic effects of peroxisomal proliferator-activated receptor γ. This study investigated the acute effect of one of the TZD, rosiglitazone, on endothelium-dependent relaxation response of corpus cavernosum (CC) in hypercholesterolemic rabbits. New Zealand rabbits were divided into two groups randomly as control and cholesterol groups. Hypercholesterolemia was induced by feeding rabbits with 2% cholesterol diet (w/w) for 6 weeks. Endothelium-dependent and -independent relaxation response of CC were evaluated in the presence of rosiglitazone by organ bath studies with cumulative doses of acetylcholine (Ach) and sodium nitroprusside (SNP). Maximal relaxation (Emax) response to Ach significantly decreased owing to hypercholesterolemia in CC tissues. However, in vitro incubation of rosiglitazone with different concentrations (0.1, 1 and 10 μm) did not improve the Ach-dependent Emax responses in hypercholesterolemic rabbit CC. Surprisingly, rosiglitazone caused a significant decrease in Ach-dependent relaxation in healthy CC. Emax responses to SNP did not differ in the presence of rosiglitazone in both the control and hypercholesterolemic groups. Rosiglitazone does not improve hypercholesterolemia-induced endothelial dysfunction in CC tissues while it dose-dependently impairs endothelium-dependent relaxation in healthy CC tissue.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27030054     DOI: 10.1038/ijir.2016.11

Source DB:  PubMed          Journal:  Int J Impot Res        ISSN: 0955-9930            Impact factor:   2.896


  26 in total

Review 1.  Thiazolidinediones.

Authors:  Hannele Yki-Järvinen
Journal:  N Engl J Med       Date:  2004-09-09       Impact factor: 91.245

2.  An increased arginase activity is associated with corpus cavernosum impairment induced by hypercholesterolemia.

Authors:  Rodrigo A Fraga-Silva; Fabiana P Costa-Fraga; Younoss Faye; Mikaël Sturny; Robson A S Santos; Rafaela F da Silva; Nikolaos Stergiopulos
Journal:  J Sex Med       Date:  2014-02-25       Impact factor: 3.802

3.  A study comparing the effects of rosiglitazone and/or insulin treatments on streptozotocin induced diabetic (type I diabetes) rat aorta and cavernous tissues.

Authors:  H Kübra Elçioğlu; Levent Kabasakal; Naziye Özkan; Çiğdem Çelikel; Gül Ayanoğlu-Dülger
Journal:  Eur J Pharmacol       Date:  2011-04-02       Impact factor: 4.432

Review 4.  Nitric oxide/redox-based signalling as a therapeutic target for penile disorders.

Authors:  Arthur L Burnett; Biljana Musicki; Liming Jin; Trinity J Bivalacqua
Journal:  Expert Opin Ther Targets       Date:  2006-06       Impact factor: 6.902

5.  Pioglitazone prevents cavernosal nerve injury after radical prostatectomy.

Authors:  Louis A Aliperti; Wayne J G Hellstrom
Journal:  Med Hypotheses       Date:  2014-01-30       Impact factor: 1.538

6.  Effects of pioglitazone on erectile dysfunction in sildenafil poor-responders: a randomized, controlled study.

Authors:  Babak Gholamine; Massoumeh Shafiei; Manijeh Motevallian; Massoud Mahmoudian
Journal:  J Pharm Pharm Sci       Date:  2008       Impact factor: 2.327

7.  Ageing-related corpora veno-occlusive dysfunction in the rat is ameliorated by pioglitazone.

Authors:  Istvan Kovanecz; Monica G Ferrini; Dolores Vernet; Gaby Nolazco; Jacob Rajfer; Nestor F Gonzalez-Cadavid
Journal:  BJU Int       Date:  2007-07-23       Impact factor: 5.588

Review 8.  The vascular endothelium in diabetes--a therapeutic target?

Authors:  Kieren J Mather
Journal:  Rev Endocr Metab Disord       Date:  2013-03       Impact factor: 6.514

9.  PPAR(gamma) agonist rosiglitazone improves vascular function and lowers blood pressure in hypertensive transgenic mice.

Authors:  Michael J Ryan; Sean P Didion; Satya Mathur; Frank M Faraci; Curt D Sigmund
Journal:  Hypertension       Date:  2004-01-26       Impact factor: 10.190

10.  Antioxidative, antinitrative, and vasculoprotective effects of a peroxisome proliferator-activated receptor-gamma agonist in hypercholesterolemia.

Authors:  Ling Tao; Hui-Rong Liu; Erhe Gao; Zhi-Ping Teng; Bernard L Lopez; Theodore A Christopher; Xin-Liang Ma; Ines Batinic-Haberle; Robert N Willette; Eliot H Ohlstein; Tian-Li Yue
Journal:  Circulation       Date:  2003-11-10       Impact factor: 29.690

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.